SuperMeat and Stämm Partner to Advance Cultivated Chicken Production

SuperMeat and Stämm, an Argentina-based biomanufacturing company, have announced a partnership to enhance cultivated chicken meat production using Stämm’s bioreactor technology. The collaboration is supported by Varana Capital, a mutual investor in both companies.

Stämm, which specializes in biopharma manufacturing, is expanding into food-tech with its Bioprocessor, an automated, continuous, bubble-free bioreactor designed to improve efficiency and scalability. SuperMeat, a cultivated meat company, recently achieved cost parity in cultivated chicken production at $11.79 per pound and will integrate Stämm’s technology in a pilot program at its facility.

The partnership aims to improve muscle fiber growth and adipocyte formation to produce organic whole-cut cultivated meat. Experimental data will assess the potential of Stämm’s technology to reduce production costs through improved culture media efficiency.

“This partnership demonstrates how complementary technologies can combine to drive progress in the cultivated meat industry,” said Ido Savir, CEO of SuperMeat.

With the alternative protein market projected to reach $290 billion by 2035, according to a report by BCG and Blue Horizon, the sector represents a significant business opportunity.

“Israel’s exceptional entrepreneurial spirit and technological prowess make it an ideal investment destination for advancing alternative protein production,” said Ezra Gardner, Co-Founder and CIO of Varana Capital.